Trial Profile
Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 03 Jan 2024 Status changed from active, no longer recruiting to completed.
- 21 Dec 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
- 08 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Nov 2022.